CorMedix Launches Catheter Lock Product In Germany, Looks Ahead To U.S.
This article was originally published in The Pink Sheet Daily
The company is shipping Neutrolin, a device containing an antimicrobial/antifungal agent and two anti-clotting agents, in Germany to “lock” catheters between dialysis sessions and prevent blood stream infections and clots. The New Jersey firm also is working with FDA to get the product approved in the U.S. as a specialty pharmaceutical.
You may also be interested in...
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Abbott earns approval in Japan for Xience Xpedition everolimus-eluting stent. Zimmer will distribute SpineCraft’s APEX system. More new product news.